Video

Dr. Branagan on Novel Induction Therapies With Transplant in Myeloma

Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

Andrew Branagan, MD, a medical oncologist at Massachusetts General Hospital Cancer Center,discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

The field of multiple myeloma has come a long way with regard to induction therapies, Branagan explains. While very good partial remission (VGPR) rates were previously less than 50%, they are now observed in two-thirds of patients. Some data have indicated that up to 100% of patients achieve VGPR with certain regimens, making it difficult to decide which approach to use. 

Currently, the standard regimen is the combination of lenalidomide (Revlimid), bortezomib (Velcade), and daratumumab (Darzalex). Some growing data suggest that current standards will probably change in the near future, concludes Branagan.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity